Uploaded August 2025 | Updated September 2026, 2 weeks ago
Tags: Artificial Intelligence, Cancer, Neurological Disorders, Alzheimers, Hemp-Derived, Cannabis Drug Development
Clayton Moore, Co-Founder of Novel Therapeutics & Drug Discovery Scientist at Rare Earth Genomics / Texas A&M University @AgriLifeVideo presents, “High-Throughput Screening and AI-Driven Discovery of Therapeutic Cannabinoids, Terpenoids, and Flavonoids for Cancer and Neurological Disorders” at CannMed 2025.
Objective
To utilize high-throughput screening and regenerative AI analysis to identify naturally derived and synthetically modified cannabinoids, terpenoids, and flavonoids with potential efficacy and safety profiles for treating cancer, Alzheimer's disease, seizures, and other conditions.
Methods
In collaboration with Texas A&M University and sponsored by Rare Earth Genomics (REG), we focused on utilizing hemp-derived molecules for our research. Advanced automation and screening platforms at our core facilities were employed, including Beckman Echo acoustic dispensers integrated into Access workstations with Cytomat cell culture incubators for 24/7 compound addition. The Tecan Evo 200 workstation with multimode readers and high-capacity Liconic incubators facilitated rapid dispensing and environmental control. A dual-arm Beckman-Coulter Biomek i7 liquid handling platform enabled precise, high-throughput liquid transfers using span-8, 96-multichannel, and single-channel dispensing heads. High-content imaging was conducted using the GE Healthcare IN Cell Analyzer 6000 and Molecular Devices ImageXpress Micro Confocal Microscope, providing detailed analysis of 2D, 3D, and spheroid cultures. We integrated regenerative AI algorithms with Novel Therapeutics' large drug databases to perform comparative analyses and pathway mapping, assisting in candidate selection for testing.
Learning Objectives:
⦾ Learn how high-throughput screening and AI accelerate therapeutic phytochemical discovery
⦾ Understand Texas A&M and Rare Earth Genomics' collaboration on hemp-derived molecules
⦾ Explore advanced automation and imaging technologies in plant-derived drug development
0:00 - Introduction
1:08 - From Ancient Medicine to Modern AI
2:17 - How AI Designs New Molecules
4:00 - Predicting Drug Interactions and Toxicity
4:54 - Retrosynthesis: From AI Design to the Lab
6:08 - High-Throughput Screening for Efficacy
7:20 - A New Paradigm: The AI-Driven Drug Discovery Loop
8:06 - The Impact of AI on Drug Development
9:05 - The High Cost and Low Success of Traditional Drug Discovery
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
Tags: Artificial Intelligence, Cancer, Neurological Disorders, Alzheimers, Hemp-Derived, Cannabis Drug Development
Clayton Moore, Co-Founder of Novel Therapeutics & Drug Discovery Scientist at Rare Earth Genomics / Texas A&M University @AgriLifeVideo presents, “High-Throughput Screening and AI-Driven Discovery of Therapeutic Cannabinoids, Terpenoids, and Flavonoids for Cancer and Neurological Disorders” at CannMed 2025.
Objective
To utilize high-throughput screening and regenerative AI analysis to identify naturally derived and synthetically modified cannabinoids, terpenoids, and flavonoids with potential efficacy and safety profiles for treating cancer, Alzheimer's disease, seizures, and other conditions.
Methods
In collaboration with Texas A&M University and sponsored by Rare Earth Genomics (REG), we focused on utilizing hemp-derived molecules for our research. Advanced automation and screening platforms at our core facilities were employed, including Beckman Echo acoustic dispensers integrated into Access workstations with Cytomat cell culture incubators for 24/7 compound addition. The Tecan Evo 200 workstation with multimode readers and high-capacity Liconic incubators facilitated rapid dispensing and environmental control. A dual-arm Beckman-Coulter Biomek i7 liquid handling platform enabled precise, high-throughput liquid transfers using span-8, 96-multichannel, and single-channel dispensing heads. High-content imaging was conducted using the GE Healthcare IN Cell Analyzer 6000 and Molecular Devices ImageXpress Micro Confocal Microscope, providing detailed analysis of 2D, 3D, and spheroid cultures. We integrated regenerative AI algorithms with Novel Therapeutics' large drug databases to perform comparative analyses and pathway mapping, assisting in candidate selection for testing.
Learning Objectives:
⦾ Learn how high-throughput screening and AI accelerate therapeutic phytochemical discovery
⦾ Understand Texas A&M and Rare Earth Genomics' collaboration on hemp-derived molecules
⦾ Explore advanced automation and imaging technologies in plant-derived drug development
0:00 - Introduction
1:08 - From Ancient Medicine to Modern AI
2:17 - How AI Designs New Molecules
4:00 - Predicting Drug Interactions and Toxicity
4:54 - Retrosynthesis: From AI Design to the Lab
6:08 - High-Throughput Screening for Efficacy
7:20 - A New Paradigm: The AI-Driven Drug Discovery Loop
8:06 - The Impact of AI on Drug Development
9:05 - The High Cost and Low Success of Traditional Drug Discovery
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
